Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses
Authors
Keywords
COVID-19, KL-6, Mucin-1
Journal
VIROLOGY
Volume 566, Issue -, Pages 106-113
Publisher
Elsevier BV
Online
2021-12-04
DOI
10.1016/j.virol.2021.11.006
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic roles of KL‐6 in disease severity and lung injury in COVID‐19 patients: A longitudinal retrospective analysis
- (2021) Kai Deng et al. JOURNAL OF MEDICAL VIROLOGY
- Characteristics of COVID-19 Patients Based on the Results of Nucleic Acid and Specific Antibodies and the Clinical Relevance of Antibody Levels
- (2021) Hao Chen et al. Frontiers in Molecular Biosciences
- Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan
- (2021) Masaru Takeshita et al. VIROLOGY
- Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia
- (2021) Riccardo Scotto et al. International Journal of Environmental Research and Public Health
- Prognostic bioindicators in severe COVID-19 patients
- (2021) L. Bergantini et al. CYTOKINE
- Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019
- (2021) Ding-Hui Peng et al. CLINICA CHIMICA ACTA
- Serum KL‐6 concentrations as a novel biomarker of severe COVID19
- (2020) Miriana d'Alessandro et al. JOURNAL OF MEDICAL VIROLOGY
- Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases
- (2020) Danli Zhong et al. MEDICINE
- Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review
- (2020) Miriana d’Alessandro et al. Biomarkers in Medicine
- Presepsin as a predictive biomarker of severity in COVID‐19: A case series
- (2020) Ai Fukada et al. JOURNAL OF MEDICAL VIROLOGY
- Peripheral biomarkers' panel for severe COVID‐19 patients
- (2020) Miriana d'Alessandro et al. JOURNAL OF MEDICAL VIROLOGY
- The role of dysregulated immune responses in COVID-19 pathogenesis
- (2020) S Tahaghoghi-Hajghorbani et al. VIRUS RESEARCH
- Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin
- (2020) Yasuhito Suzuki et al. INTERNAL MEDICINE
- Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis
- (2019) Chaojun Hu et al. CLINICAL RHEUMATOLOGY
- MUC1: The First Respiratory Mucin with an Anti-Inflammatory Function
- (2017) Kosuke Kato et al. Journal of Clinical Medicine
- Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6
- (2013) Ling Xu et al. EXPERIMENTAL LUNG RESEARCH
- Serum KL-6 Level as an Indicator of Active or Inactive Interstitial Pneumonitis Associated with Connective Tissue Diseases
- (2011) Satoshi Doishita et al. INTERNAL MEDICINE
- Hepatocyte Growth Factor Inhibits Epithelial to Myofibroblast Transition in Lung Cells via Smad7
- (2008) Manasi N. Shukla et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation
- (2008) Nikolaos A Patsopoulos et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More